PTEN and neoplasm: Irrespective of NSCLC subtype, patient data suggest that PTEN loss is a direct prognostic marker for shorter survival, including tumor mutational burden (TMB) low patients, which are otherwise not amenable to immunotherapy and treated with chemotherapy (Additional file 1: Fig. S1A).